Metraipolis › archive › dc_4146e67a4e83

Real-world lipid outcomes after switching PCSK9-targeting therapies in heterozygous familial hypercholesterolemia: the SHIFT-FH study — Europe PMC PMID:42287585

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42287585
DOI
10.1007/s11739-[numero omesso]-8
License (as archived)
solo-consultazione
Archived
2026-10-31T12:25:05.090Z
SHA-256 of the archived text
ec3e683e11d2effa50f31ed9a8f93f7984199263210147be267d7914e0423b57
Stable URL of this page
https://metraipolis.com/documento/dc_4146e67a4e83

How to cite

Real-world lipid outcomes after switching PCSK9-targeting therapies in heterozygous familial hypercholesterolemia: the SHIFT-FH study — Europe PMC PMID:42287585 — Europe PMC (en), https://europepmc.org/article/MED/42287585 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4146e67a4e83 (Metraipolis archive dc_4146e67a4e83, sha256 ec3e683e11d2effa50f31ed9a8f93f7984199263210147be267d7914e0423b57)
BibTeX
@misc{dc4146e67a4e83,
  title = {Real-world lipid outcomes after switching PCSK9-targeting therapies in heterozygous familial hypercholesterolemia: the SHIFT-FH study — Europe PMC PMID:42287585},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42287585},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4146e67a4e83; sha256 ec3e683e11d2effa50f31ed9a8f93f7984199263210147be267d7914e0423b57},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42287585. Agents can read the archived copy with the MCP tool read_document.